KNTE - Kinnate Biopharma Inc.

QQQ $ 426.89 $ 1.59 (0.37 %)

DIA $ 382.25 $ 0.64 (0.17 %)

SPY $ 504.90 $ 0.50 (0.1 %)

TLT $ 88.95 $ 0.73 (0.83 %)

GLD $ 213.44 $ 0.98 (0.46 %)

Previous Close

$ 2.65

Open

$ 2.67

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 2.64 - $ 2.67

52 Week Range

$ 1.04 - $ 7.19

Volume

2,812,224

Average Volume

Market Cap

123.42M

Beta (5Y Monthly)

$ 1.82

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	03-28-2024	12-31-2023	10-K
2	11-09-2023	09-30-2023	10-Q
3	08-08-2023	06-30-2023	10-Q
4	05-11-2023	03-31-2023	10-Q
5	03-15-2023	12-31-2022	10-K
6	11-10-2022	09-30-2022	10-Q
7	08-11-2022	06-30-2022	10-Q
8	05-12-2022	03-31-2022	10-Q
9	03-28-2022	12-31-2021	10-K
10	11-10-2021	09-30-2021	10-Q
11	08-16-2021	06-30-2021	10-Q
12	05-17-2021	03-31-2021	10-Q
13	03-29-2021	12-31-2020	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

XOMA Corp Entered Into A Merger Agreement ...
03/19/2024 20:15:36

As previously announced on February 16, 2024, XOMA Corporation (("XOMA" or the "Company", NASDAQ:XOMA) entered ...

Kinnate Biopharma Inc. Sells Its Investiga...
03/01/2024 13:33:57

Kinnate has entered into an Asset Purchase Agreement (the "APA") with Pierre Fabre Laboratories for global rights to ex...

biotech-royalty-aggregator-xoma-to-acquire-small-cancer-drug-developer-kinnate-biopharma

Biotech Royalty Aggregator XOMA To Acquire...
02/16/2024 17:55:15

XOMA acquires Kinnate Biopharma for $2.3352 per share, with potential additional cash. The acquisition is expected to close in ...

Trading Halt: Halt status updated at 8:25:...
02/16/2024 13:25:05

XOMA Enters Agreement To Acquire Kinnate B...
02/16/2024 13:02:10

Wedbush Reiterates Neutral on Kinnate Biop...
01/17/2024 13:32:50

Wedbush analyst David Nierengarten reiterates Kinnate Biopharma (NASDAQ:KNTE) with a Neutral and maintains $2 price target.

why-shapeways-holdings-shares-are-trading-lower-by-around-20-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Why Shapeways Holdings Shares Are Trading ...
11/15/2023 19:04:31

Shares of Shapeways Holdings, Inc. (NASDAQ: SHPW) tumbled during Wednesday’s session following downbeat results.

12-health-care-stocks-moving-in-wednesdays-intraday-session

12 Health Care Stocks Moving In Wednesday'...
11/15/2023 17:31:41

why-is-cancer-focused-kinnate-biopharma-stock-trading--higher-today

Why is Cancer-Focused Kinnate Biopharma St...
11/15/2023 15:02:55

Kinnate Biopharma Inc's (NASDAQ: KNTE) board of directors received a letter from Foresite Capital Management and OrbiMed Ad...

Kinnate Biopharma Says Letter Indicated In...
11/15/2023 14:23:34

-SEC 8K Filing

On Nov 13, Kinnate Biopharma Board Got Let...
11/15/2023 14:23:06

-SEC 8K Filing

Market-Moving News for November 15th
11/15/2023 13:48:11

SPRC: 106% | SciSparc Celebrates Major Breakthrough: Positive Results Show its Treatment has a Remarkable Impact on Alzheimer&#...

12-health-care-stocks-moving-in-wednesdays-pre-market-session

12 Health Care Stocks Moving In Wednesday'...
11/15/2023 13:06:37

Foresite Capital Fund In Amended 13D Filin...
11/15/2023 12:16:28

Kinnate Biopharma Q3 EPS $(0.65) Beats $(0...
11/09/2023 22:37:35

Kinnate Biopharma (NASDAQ:KNTE) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of $(0...

Stocks That Hit 52-Week Lows On Thursday
10/05/2023 17:22:02

On Thursday, 369 companies hit new 52-week lows.

analysts-move-to-sidelines-for-cancer-player-kinnate-biopharma-after-restructuring

Analysts Move To Sidelines For Cancer Play...
09/19/2023 18:20:14

Monday, Kinnate Biopharma Inc (NASDAQ: KNTE) prioritized the exarafenib combination, KIN-8741, and discovery efforts around its

Jefferies Maintains Buy on Kinnate Biophar...
09/19/2023 15:17:46

Jefferies analyst Roger Song maintains Kinnate Biopharma (NASDAQ:KNTE) with a Buy and lowers the price target from $31 to $2.

Benzinga's Top Ratings Upgrades, Downgrade...
09/19/2023 15:00:28

why-is-cancer-firm-kinnate-biopharma-stock-trading-lower-today

Why Is Cancer Firm Kinnate Biopharma Stock...
09/19/2023 13:15:19

Kinnate Biopharma Inc (NASDAQ: KNTE) announced pipeline updates, a reprioritization plan, and workforce restructuring to